ERBB2 and breast carcinoma: CB-839 treatment inhibited the proliferation of the triple-negative breast cancer (TNBC) cell lines, HCC1806 and MDA-MB-231, (IC50 of 49.0 and 26.0 nmol/L, respectively), but had no effect on the viability of the breast cancer ER+/HER2− cell line T47D.